---
title: "Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash Runway"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297940103.md"
description: "LifeSci Capital analyst Sam Slutsky reiterated a Buy rating on Attovia Therapeutics with a $45 price target, citing strong early Phase 1b data for ATTO-1310 and a robust cash runway extending to 2030. Morgan Stanley also assigned a Buy rating with a $39 target."
datetime: "2026-09-03T15:55:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297940103.md)
  - [en](https://longbridge.com/en/news/297940103.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297940103.md)
generator: "portal-rs"
---

# Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash Runway

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Attovia Therapeutics, Inc.. The associated price target remains the same with $45.00.

Sam Slutsky has given his Buy rating due to a combination of factors tied to Attovia’s clinical progress and financial strength. He highlights that early Phase 1b results for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis show compelling reductions in itch scores and meaningful improvements in disease severity, with durable IL-31 suppression supporting infrequent dosing and suggesting competitive differentiation versus existing biologics.

He also points to the company’s solid balance sheet, with over $115M in cash at quarter-end plus more than $300M in net IPO proceeds, providing funding visibility into 2030 and reducing financing risk through upcoming milestones. In addition, Attovia is preparing global Phase 2 trials in chronic pruritus of unknown origin and high-itch AD for the first half of 2027, which could serve as important value inflection points, and he maintains a $45 price target reflecting this favorable risk‑reward profile.

In another report released today, Morgan Stanley also assigned a Buy rating to the stock with a $39.00 price target.

### Related Stocks

- [ATTO.US](https://longbridge.com/en/quote/ATTO.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Attovia's Q2 Loss Expands With Increased Trials For ATTO-1310; Plans Phase 2 For Q1 '27](https://longbridge.com/en/news/297941843.md)
- [ATTO: Lead program shows clinical proof of concept; IPO funds extend cash runway into 2030](https://longbridge.com/en/news/297826808.md)
- [Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End  on September 14th](https://longbridge.com/en/news/298168859.md)
- [Attovia Therapeutics (NASDAQ:ATTO) Upgraded by Royal Bank Of Canada to "Moderate Buy" Rating](https://longbridge.com/en/news/297636916.md)
- [Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital](https://longbridge.com/en/news/297470988.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**